Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Banking & FMCG, major gainers
Fri, 21 Feb 01:30 pm

Indian share markets continued to trade high in the post-noon trading session. Barring realty, all the sectoral indices are trading in the green with banking, FMCG and IT stocks being the major gainers.

BSE-Sensex is up 158 points and NSE-Nifty is trading 55 points up. Both BSE Mid Cap and BSE Small Cap indices are trading up by 0.7% each. The rupee is trading at 62.1 to the US dollar.

Most of the Indian pharma stocks are trading in the green with Natco Pharma and Dishman Pharma being the major gainers whereas Panacea Biotech and Ranbaxy Labs are among the few stocks trading in the red. As per a leading financial daily, Indian Drug Manufacturer's Association (IDMA) has partnered with global safety science company UL to empower domestic pharma companies in meeting increased compliance levels and navigating complex regulatory issues. The move comes on the back of a number of domestic pharma companies being issued import alerts and bans by US Food & Drug Administration (USFDA). As per IDMA, domestic pharma companies are going wrong not due to lack of intent but rather lack of information. UL will offer training to domestic pharma companies in good manufacturing practices (GMP) guidelines, rightful implementation and full proof audit processes to ensure consistency.

Majority of the PSU banking stocks are trading in the green with Indian Bank and State Bank of India (SBI) being among major gainers whereas United Bank of India and Bank of Maharashtra are among the few stocks trading in the red. As per a leading financial daily the chairperson and managing director of United Bank of India took a voluntary retirement on concerns of growing non-performing assets (NPA). The bank posted a net loss of Rs 12.4 bn in the December 2013 quarter due to higher provisioning for bad loans. In proportion to advances, the bank's gross NPA rose to 10.8% from 4.4% whereas net NPA increased to 7.4% from 2.2%. The bank has made provision of Rs 18.5 bn towards NPA which was more than four times, the bank provided for in the year-ago period. United Bank of India's stock is down by 1.4%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Banking & FMCG, major gainers". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.